| Literature DB >> 28819298 |
Natallia Shved1, Gregor Warsow2, Felix Eichinger3, David Hoogewijs4, Simone Brandt5, Peter Wild5, Matthias Kretzler3, Clemens D Cohen1,6, Maja T Lindenmeyer7,8.
Abstract
Accumulating evidence suggests that dysregulation of hypoxia-regulated transcriptional mechanisms is involved in development of chronic kidney diseases (CKD). However, it remains unclear how hypoxia-induced transcription factors (HIFs) and subsequent biological processes contribute to CKD development and progression. In our study, genome-wide expression profiles of more than 200 renal biopsies from patients with different CKD stages revealed significant correlation of HIF-target genes with eGFR in glomeruli and tubulointerstitium. These correlations were positive and negative and in part compartment-specific. Microarrays of proximal tubular cells and podocytes with stable HIF1α and/or HIF2α suppression displayed cell type-specific HIF1/HIF2-dependencies as well as dysregulation of several pathways. WGCNA analysis identified gene sets that were highly coregulated within modules. Characterization of the modules revealed common as well as cell group- and condition-specific pathways, GO-Terms and transcription factors. Gene expression analysis of the hypoxia-interconnected pathways in patients with different CKD stages revealed an increased dysregulation with loss of renal function. In conclusion, our data clearly point to a compartment- and cell type-specific dysregulation of hypoxia-associated gene transcripts and might help to improve the understanding of hypoxia, HIF dysregulation, and transcriptional program response in CKD.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28819298 PMCID: PMC5561250 DOI: 10.1038/s41598-017-08492-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Spearman Correlation Analysis for selected HIF-target genes with eGFR.
| Entrez Gene ID | Gene Symbol | eGFR (Glom) | eGFR (Tub) |
|---|---|---|---|
| ρ | ρ | ||
| 9429 | ABCG2 |
| |
| 226 | ALDOA | − | |
| 79365 | BHLHE41 | − |
|
| 664 | BNIP3 |
| |
| 10370 | CITED2 |
| |
| 1356 | CP | − | |
| 7852 | CXCR4 | − |
|
| 54541 | DDIT4 | − | |
| 1906 | EDN1 |
| |
| 2023 | ENO1 | − | − |
| 26355 | FAM162A |
| |
| 2235 | FECH |
| |
| 2597 | GAPDH | − | |
| 3091 | HIF1A | −0.402 |
|
| 7184 | HSP90B1 | − | |
| 3484 | IGFBP1 | − | |
| 3486 | IGFBP3 | − | |
| 3689 | ITGB2 |
|
|
| 4015 | LOX |
| |
| 4017 | LOXL2 | − | − |
| 4170 | MCL1 | − |
|
| 4233 | MET |
| |
| 4601 | MXI1 |
| |
| 10397 | NDRG1 |
|
|
| 4878 | NPPA |
| |
| 5209 | PFKFB3 |
|
|
| 5366 | PMAIP1 | − | − |
| 6095 | RORA |
| |
| 5054 | SERPINE1 | − | |
| 7037 | TFRC | − | |
| 7422 | VEGFA |
| |
| 7490 | WT1 |
|
Bold: ρ > І0.4І, adjusted p < 0.05; Italic: І0.4І > ρ > І0.3І, adjusted p < 0.05.
Figure 1Immunohistochemistry of HIF1α, VEGFA and ABCG2. Sections from paraffin embedded kidney biopsies with chronic kidney disease (normal (left) and reduced eGFR (right)) were stained with antibodies against HIF1α (A), ATP binding cassette subfamily G member 2 (ABCG2) (B), and vascular endothelial growth factor A (VEGFA) (C). (A) No specific HIF1α staining could be detected in kidney sections with normal eGFR, score negative (0). Only some unspecific intravascular background staining is seen (left). In kidneys from patients with severely reduced eGFR, some nuclear (→) and cytoplasmic (►) tubular staining is detected, score weak (1) (right). (B) ABCG2 showing strong (score 2) expression in the tubulointerstitial compartment of kidneys with normal eGFR (left) in contrast to weak (score 1) staining in samples with reduced eGFR (right). (C) Similar stainig pattern for VEGFA, strong (score 2) expression in the tubulointerstitial compartment of kidneys with normal eGFR (left) in contrast to weak (score 1) staining in samples with reduced eGFR (right).
Figure 2Scheme describing the workflow of microarray analysis.
Figure 3GO enrichment analysis: network visualization for the common and exclusively enriched GOs in the different cell lines using the Cytoscape plugins BinGO and EnrichmentMap. Red nodes represent enriched GO-terms, node size corresponds to negative logarithm of FDR-corrected p-value. Edge thickness shows overlap of genes between neighbor nodes. Figures (A) and (B) represent networks of GO-Terms which are exclusively associated with AB81 (A) and HK-2 (B) under hypoxic condition, figure (C) displays the network of common GO-Terms in AB81 and HK-2 under hypoxia. Figures (D–E) show the exlusive AB81 (D), HK-2 (E) GO-Terms under normoxic conditions. There were no common GO-Terms under normoxic conditions.
Figure 4Transcription factor (TF) - gene regulatory networks (under hypoxic conditions). The podocyte TF-gene network (A) consists of 1837 nodes, 53175 edges. The tubular network (B) is compiled of 775 nodes and 24799 edges. Figure (C) shows the intersection of the podocyte and tubular network. Red nodes represent transcription factors, white nodes correspond to regulated genes. Edges connect TFs with their target genes.
Figure 5Transcription factor (TF) - gene regulatory networks (under normoxic conditions). The podocyte TF-gene network (A) consists of 2275 nodes, 63209 edges. The tubular network (B) is compiled of 1255 nodes and 21204 edges. Figure (C) shows the intersection of the podocyte and tubular network. Red nodes represent transcription factors, white nodes correspond to regulated genes. Edges connect TFs with their target genes.
Summary of canonical signal transduction pathways.
| Canonical pathway | Pathway id | AB81_exclusive network | HK2_exclusive network | Intersection AB81_HK2 | |||
|---|---|---|---|---|---|---|---|
| p-value | Adj p-value | p-value | Adj p-value | p-value | Adj p-value | ||
| Alk in cardiac myocytes | BioCarta:alkpathway | 1.73E-04 | 0.00E+00 | 4.23E-04 | 1.00E-03 | ||
| BMP2 signaling pathway(through Smad) | INOH:BMP2_signaling_TGF-beta_MV | 8.70E-03 | 8.00E-03 | 2.17E-04 | 0.00E+00 | ||
| Circadian rhythm pathway | NCI-nature:circadianpathway | 2.30E-03 | 2.00E-03 | ||||
| HIF-1-alpha transcription factor network | NCI-nature:hif1_tfpathway | 8.80E-05 | 0.00E+00 | 6.26E-04 | 0.00E+00 | ||
| HIF-2-alpha transcription factor network | NCI-nature:hif2pathway | 1.79E-03 | 2.00E-03 | 1.80E-03 | 2.00E-03 | 1.77E-04 | 0.00E+00 |
| Hypoxic and oxygen homeostasis regulation of HIF-1-alpha | NCI-nature:hif1apathway | 6.12E-03 | 1.00E-02 | 3.21E-03 | 3.00E-03 | ||
| ID | CellMap:ID | 3.40E-04 | 0.00E+00 | 7.95E-03 | 6.00E-03 | ||
| Mets affect on macrophage differentiation | BioCarta:etspathway | 2.73E-03 | 2.00E-03 | ||||
| Angiopoietin receptor Tie2-mediated signaling | NCI-nature:angiopoietinreceptor_pathway | 1.02E-03 | 2.00E-03 | ||||
| Estrogen responsive protein efp controls cell cycle and breast tumors growth | BioCarta:efppathway | 2.33E-03 | 0.00E+00 | ||||
| nfkb activation by nontypeable hemophilus influenzae | BioCarta:nthipathway | 2.08E-03 | 3.00E-03 | ||||
| NOTCH | CellMap:NOTCH | 1.84E-03 | 3.00E-03 | ||||
| AP-1 transcription factor network | NCI-nature:ap1_pathway | 9.35E-06 | 0.00E+00 | ||||
| EGFR1 | CellMap:EGFR1 | 5.30E-03 | 1.00E-03 | ||||
| Mapkinase signaling pathway | BioCarta:mapkpathway | 4.92E-03 | 5.00E-03 | ||||
| Overview of telomerase protein component gene htert transcriptional regulation | BioCarta:tertpathway | 5.37E-03 | 7.00E-03 | ||||
| Regulation of retinoblastoma protein | NCI-nature:rb_1pathway | 3.57E-03 | 4.00E-03 | ||||
| Signaling mediated by p38-alpha and p38-beta | NCI-nature:p38alphabeta-downstreampathway | 1.00E-04 | 0.00E+00 | ||||
Adjusted p-value: corresponds to a p-value that is estimated from the results of 1,000 simulated null hypothesis queries[65].
Summary of canonical signal transduction pathways (Normoxia).
| Canonical pathway | Pathway id | AB81_exclusive network | HK2_exclusive network | Intersection AB81_HK2 | |||
|---|---|---|---|---|---|---|---|
| P-value | Adj p-value | P-value | Adj p-value | P-value | Adj p-value | ||
| AKT(PKB) activation signaling (Insulin receptor signaling (Mammal)) | INOH:insulin_Mam | 8.28E-03 | 6.00E-03 | ||||
| Beta1 integrin cell surface interactions | NCI-nature:integrin1_pathway | 1.08E-03 | 1.00E-03 | ||||
| BMP receptor signaling | NCI-nature:bmppathway | 2.18E-03 | 1.00E-03 | ||||
| BMP2 signaling pathway(through TAK1) | INOH:BMP2_signaling_TAK1 | 1.68E-03 | 2.00E-03 | 8.61E-03 | 9.00E-03 | ||
| CXCR3-mediated signaling events | NCI-nature:cxcr3pathway | 4.29E-04 | 0.00E + 00 | 4.27E-03 | 3.00E-03 | ||
| human cytomegalovirus and map kinase pathways | BioCarta:hcmvpathway | 2.05E-03 | 0.00E + 00 | ||||
| PDGFR-beta signaling pathway | NCI-nature:pdgfrbpathway | 3.12E-03 | 2.00E-03 | 1.54E-03 | 2.00E-03 | ||
| A6b1 and a6b4 Integrin signaling | NCI-nature:a6b1_a6b4_integrin_pathway | 6.88E-03 | 4.00E-03 | ||||
| Aspirin blocks signaling pathway involved in platelet activation | BioCarta:sppapathway | 3.52E-03 | 4.00E-03 | ||||
| ATF-2 transcription factor network | NCI-nature:atf2_pathway | 5.16E-03 | 7.00E-03 | ||||
| Aurora B signaling | NCI-nature:aurora_b_pathway | 9.19E-03 | 5.00E-03 | ||||
| Ctcf: first multivalent nuclear factor | BioCarta:ctcfpathway | 4.21E-03 | 5.00E-03 | ||||
| EGF receptor proximal signaling | NCI-nature:erbb1_receptor_proximal_pathway | 2.70E-03 | 2.00E-03 | ||||
| EPHB forward signaling | NCI-nature:ephbfwdpathway | 2.20E-03 | 3.00E-03 | ||||
| Internalization of ErbB1 | NCI-nature:erbb1_internalization_pathway | 4.30E-03 | 5.00E-03 | ||||
| Nfkb activation by nontypeable hemophilus influenzae | BioCarta:nthipathway | 1.33E-03 | 1.00E-03 | ||||
| p38 cascade (TGF-beta signaling(through TAK1)) | INOH:TGF-beta_signaling_TAK1 | 1.71E-03 | 3.00E-03 | ||||
| p38 signaling mediated by MAPKAP kinases | NCI-nature:p38_mk2pathway | 2.36E-03 | 2.00E-03 | ||||
| Phosphorylation of mek1 by cdk5/p35 down regulates the map kinase pathway | BioCarta:cdk5pathway | 7.31E-03 | 6.00E-03 | ||||
| Plasma membrane estrogen receptor signaling | NCI-nature:er_nongenomic_pathway | 8.93E-04 | 0.00E + 00 | ||||
| Ras signaling in the CD4 + TCR pathway | NCI-nature:tcrraspathway | 7.31E-03 | 3.00E-03 | ||||
| RXR and RAR heterodimerization with other nuclear receptor | NCI-nature:rxr_vdr_pathway | 1.39E-04 | 0.00E + 00 | ||||
| Signaling mediated by p38-alpha and p38-beta | NCI-nature:p38alphabetadownstreampathway | 7.69E-03 | 8.00E-03 | ||||
| Tgf beta signaling pathway | BioCarta:tgfbpathway | 8.63E-03 | 8.00E-03 | ||||
| Trk receptor signaling mediated by PI3K and PLC-gamma | NCI-nature:pi3kplctrkpathway | 1.40E-03 | 1.00E-03 | ||||
| Alpha-synuclein signaling | NCI-nature:alphasynuclein_pathway | 6.14E-03 | 5.00E-03 | ||||
| Alternative NF-kappaB pathway | NCI-nature:nfkappabalternativepathway | 7.67E-03 | 7.00E-03 | ||||
| Amb2 Integrin signaling | NCI-nature:amb2_neutrophils_pathway | 5.82E-03 | 5.00E-03 | ||||
| Calcium signaling in the CD4 + TCR pathway | NCI-nature:tcrcalciumpathway | 4.85E-03 | 3.00E-03 | ||||
| FoxO family signaling | NCI-nature:foxopathway | 6.34E-03 | 5.00E-03 | ||||
| IL12 signaling mediated by STAT4 | NCI-nature:il12_stat4pathway | 1.17E-03 | 2.00E-03 | ||||
| Role of Calcineurin-dependent NFAT signaling in lymphocytes | NCI-nature:nfat_3pathway | 1.32E-03 | 1.00E-03 | ||||
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | NCI-nature:fra_pathway | 9.37E-03 | 9.00E-03 | ||||
Adjusted p-value: corresponds to a p-value that is estimated from the results of 1,000 simulated null hypothesis queries[65].
Figure 6Visualization of the interplay of the significantly enriched pathways in CKD development progression. Increased dysregulation of the hypoxia-interconnected pathways with loss of renal function in glomerular (A) and tubulointerstitial (B) samples. Color represents the log2 expression foldchange, node size the absolute value of the log2 foldchange, edge color represents the pathway. Directionality is based on pathway information and represented by arrows. Red means upregulated, blue downregulated compared to CKD1.